Director Declaration
June 22, 2017 - Shire plc
(LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that Flemming
Ornskov, MD, MPH, Chief Executive Officer of the Company, was
appointed to the Board of Directors of Waters Corporation on
June 22, 2017.
This notification is to satisfy the Company’s obligations under
LR 9.6.14R of the UK Listing Rules.
Stephen Williams
Deputy Company Secretary
For further information please
contact:
| Investor
Relations |
|
|
| Ian Karp |
ikarp@shire.com |
+1 781
482 9018 |
| Robert Coates |
rcoates@shire.com |
+44 1256
894874 |
| Media |
|
|
| Lisa Adler |
lisa.adler@shire.com |
+1 617
588 8607 |
| Debbi Ford |
debbi.ford@shire.com |
+1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on
serving people with rare diseases. We strive to develop
best-in-class products, many of which are available in more than
100 countries, across core therapeutic areas including Hematology,
Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders,
Gastrointestinal / Internal Medicine / Endocrine and Hereditary
Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to
develop and deliver breakthrough therapies for the hundreds of
millions of people in the world affected by rare diseases and other
high-need conditions, and who lack effective therapies to live
their lives to the fullest.
www.shire.com